<DOC>
	<DOCNO>NCT01352039</DOCNO>
	<brief_summary>The primary objective endpoint study compare efficacy two product contain heparin sodium , evaluate formulation produce Eurofarma consider non-inferior reference product .</brief_summary>
	<brief_title>A Non-inferiority Study Comparing Two Heparin Sodium Preparations Hip Fracture Surgery</brief_title>
	<detailed_description>The primary objective study assess efficacy unfractionated heparin sodium porcine origin ( Eurofarma ) prophylaxis VTE relative unfractionated heparin sodium porcine origin APP Pharmaceuticals . The primary endpoint frequency DVT determine Doppler ultrasound ( DUS ) .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>In order enrol study , eligible patient must meet criterion : ICF signing ; Aged 60 85 year old ; Indication hip orthopedic surgery due fracture occur within last 5 day ; Normal coagulation profile alteration 25 % normal value . Patients meet follow criterion eligible study : Previous hip surgery ; Fracture secondary presence metastasis ; Recent traumatic brain , thoracic , abdominal injury ( 30 day study start ) ; Recent occurrence ( 30 day study start ) cerebrovascular accident ; Serum concentration hemoglobin 9 g/dL ; Prior occurrence ( last 5 year ) confirm suspect thromboembolic event ; Occurrence major bleed last 6 month ( spontaneous gastrointestinal bleeding ; central nervous system bleeding ; massive epistaxis , gum bleeding ; gross hematuria , vaginal bleeding ) ; Confirmed suspect blood dyscrasia ; Diagnosis neoplasm situ last 24 month active neoplasm ( neoplasms situ prevent patient participate ) ; Liver kidney failure ; Clinically significant gastrointestinal cardiovascular , neurological disease , laboratory abnormality , investigator 's opinion , may interfere individual 's participation study assessment individual 's response treatment ; Hypersensitivity heparin ; Previous use ( 15 day study start ) oral anticoagulant expect use study ( see Appendix B ) ; Recent participation ( previous 12 month ) clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Heparin Sodium</keyword>
	<keyword>Thromboprophylaxis</keyword>
	<keyword>Hip Fracture Surgery .</keyword>
</DOC>